CN113907361A - Probiotic compositions - Google Patents

Probiotic compositions Download PDF

Info

Publication number
CN113907361A
CN113907361A CN202110868732.2A CN202110868732A CN113907361A CN 113907361 A CN113907361 A CN 113907361A CN 202110868732 A CN202110868732 A CN 202110868732A CN 113907361 A CN113907361 A CN 113907361A
Authority
CN
China
Prior art keywords
parts
lactobacillus
bifidobacterium
probiotic composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110868732.2A
Other languages
Chinese (zh)
Inventor
文可珍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunan Dayu Technology Co ltd
Original Assignee
Hunan Dayu Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunan Dayu Technology Co ltd filed Critical Hunan Dayu Technology Co ltd
Priority to CN202110868732.2A priority Critical patent/CN113907361A/en
Publication of CN113907361A publication Critical patent/CN113907361A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/01—Instant products; Powders; Flakes; Granules
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
    • A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/113—Acidophilus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/165—Paracasei
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/169—Plantarum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/515—Animalis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/531—Lactis

Abstract

The invention discloses a probiotic composition which comprises 15-25 parts by mass of freeze-dried bacteria powder and 75-85 parts by mass of auxiliary materials, wherein the freeze-dried bacteria powder comprises lactobacillus acidophilus, bifidobacterium lactis, lactobacillus rhamnosus, lactobacillus paracasei, bifidobacterium animalis, lactobacillus plantarum and lactobacillus, and the auxiliary materials comprise inulin, fructo-oligosaccharide, sea buckthorn powder, polydextrose, lactitol, erythritol and isomerized lactose. The probiotic composition can regulate intestinal functions, increase the absorption capacity of a human body and regulate the functions of the human body from multiple aspects.

Description

Probiotic compositions
Technical Field
The invention relates to the technical field of food, and particularly relates to a probiotic composition.
Background
The gastrointestinal tract of a healthy person is populated by a wide variety of microorganisms, which are referred to as intestinal flora. The intestinal flora is combined according to a certain proportion, the bacteria are restricted and dependent with each other, an ecological balance is formed on the quality and quantity, once the internal and external environments of the organism change, the flora imbalance is caused, the normal physiological combination of the organism is destroyed, the pathological combination is generated, and the clinical symptoms are called the intestinal flora imbalance. Probiotics are a class of microorganisms that have a beneficial effect on the human body, and can intervene at the level of the intestinal flora by hindering the growth of pathogenic microorganisms and/or by acting more directly on the immune system.
The environment deterioration and unhealthy life style are accompanied by the increase of life pressure, more and more people generate emotions such as anxiety, depression and the like due to the excessive mental pressure to cause dysfunction of a neuroendocrine system, most of sensitive bacteria and normal flora can be inhibited or killed after the modern society uses a large amount of broad-spectrum antibiotics for a long time, while drug-resistant bacteria can be propagated in a large amount due to the selection action of the antibiotics, and the factors can cause physiological dysfunction of intestinal tracts, unbalance the micro-ecological environment in the intestinal tracts, further cause abnormal digestion and absorption functions and body metabolic disorder.
Therefore, there is a need to provide a new food product to solve the above technical problems.
Disclosure of Invention
The invention mainly aims to provide a probiotic composition, and aims to provide a novel food to solve the technical problem of abnormal human intestinal flora.
In order to achieve the purpose, the probiotic composition provided by the invention comprises 15-25 parts by mass of freeze-dried bacteria powder and 75-85 parts by mass of auxiliary materials, wherein the freeze-dried bacteria powder comprises lactobacillus acidophilus, bifidobacterium lactis, lactobacillus rhamnosus, bifidobacterium animalis, lactobacillus paracasei, lactobacillus plantarum and lactobacillus, and the auxiliary materials comprise inulin, fructo-oligosaccharide, sea buckthorn powder, polydextrose, lactitol, erythritol and isomerized lactose.
Preferably, the freeze-dried powder comprises, by mass, 4-7 parts of lactobacillus acidophilus, 5-50 parts of bifidobacterium lactis, 2-4 parts of lactobacillus rhamnosus, 2-4 parts of bifidobacterium animalis, 2-4 parts of lactobacillus paracasei, 2-4 parts of lactobacillus plantarum and 4-6 parts of lactic acid bacteria.
Preferably, the lactobacillus acidophilus is lactobacillus acidophilus NCFM.
Preferably, the bifidobacterium lactis comprises bifidobacterium lactis HN-019, bifidobacterium lactis Bi-07, bifidobacterium lactis BL-04 and bifidobacterium lactis BLC 1.
Preferably, the lactobacillus rhamnosus is lactobacillus rhamnosus GG.
Preferably, the bifidobacterium animalis is bifidobacterium animalis Bb-12.
Preferably, the lactobacillus paracasei is lactobacillus paracasei LPC-37.
Preferably, the lactobacillus plantarum is lactobacillus plantarum BG 112.
Preferably, the lactic acid bacteria are YO-MIX725 lactic acid bacteria and YO-MIX863 lactic acid bacteria.
Preferably, the auxiliary materials comprise, by mass, 25-30 parts of inulin, 25-30 parts of fructo-oligosaccharide, 5-10 parts of sea buckthorn powder, 5-10 parts of polydextrose, 5-10 parts of lactitol, 5-10 parts of erythritol and 5-10 parts of isomerized lactose.
In the technical scheme of the invention, the combination of the bifidobacteria and the lactic acid bacteria can inhibit the growth of harmful bacteria of a human body, resist the infection of pathogenic bacteria, synthesize vitamins required by the human body, promote the absorption of the human body to mineral substances, generate organic acids such as acetic acid, propionic acid, butyric acid, lactic acid and the like to stimulate the intestinal tract to creep, promote defecation, prevent constipation, inhibit the putrefaction of the intestinal tract, purify the intestinal environment, decompose carcinogenic substances and stimulate the immune system of the human body, thereby improving the disease resistance; the lactobacillus rhamnosus can promote the growth of bifidobacterium and lactobacillus acidophilus; the lactobacillus paracasei can tolerate low pH value and can survive in bile juice, the time for other probiotics to adhere to mucosa on the inner wall of the intestinal tract is prolonged, the specific immune response is improved, and the immune system is beneficially adjusted; the composition can be combined with Lactobacillus acidophilus to promote gastrointestinal health, improve immunity, and prevent and resist influenza bacteria; by setting the isomerized lactose, a sugar source is provided for the growth of the bifidobacteria, and the growth advantage of the bifidobacteria is improved.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Moreover, the technical solutions in the embodiments of the present invention may be combined with each other, but it is necessary to be able to be realized by a person skilled in the art, and when the technical solutions are contradictory or cannot be realized, the combination of the technical solutions should be considered to be absent, and is not within the protection scope of the present invention.
The present invention will be further illustrated by the following examples and comparative examples. The following examples are merely exemplary of the present invention, and the scope of the present invention is not limited thereto.
The probiotic composition provided by the invention comprises 15-25 parts by mass of freeze-dried bacteria powder and 75-85 parts by mass of auxiliary materials, wherein the freeze-dried bacteria powder comprises lactobacillus acidophilus, bifidobacterium lactis, lactobacillus rhamnosus, bifidobacterium animalis, lactobacillus paracasei, lactobacillus plantarum and lactobacillus, and the auxiliary materials comprise inulin, fructo-oligosaccharide, sea buckthorn powder, polydextrose, lactitol, erythritol and isomerized lactose.
The freeze-dried powder comprises, by mass, 4-7 parts of lactobacillus acidophilus, 5-50 parts of bifidobacterium lactis, 2-4 parts of lactobacillus rhamnosus, 2-4 parts of bifidobacterium animalis, 2-4 parts of lactobacillus paracasei, 2-4 parts of lactobacillus plantarum and 4-6 parts of lactic acid bacteria.
The lactobacillus acidophilus is lactobacillus acidophilus NCFM; the Bifidobacterium lactis comprises Bifidobacterium lactis HN-019, Bifidobacterium lactis Bi-07, Bifidobacterium lactis BL-04, and Bifidobacterium lactis BLC 1; the lactobacillus rhamnosus is lactobacillus rhamnosus GG; the bifidobacterium animalis is bifidobacterium animalis Bb-12; the lactobacillus paracasei is lactobacillus paracasei LPC-37; the lactobacillus plantarum is lactobacillus plantarum BG 112; the lactobacillus is YO-MIX725 lactobacillus and YO-MIX863 lactobacillus.
The auxiliary materials comprise inulin, fructo-oligosaccharide, polydextrose, sea buckthorn powder, lactitol, erythritol and isomerized lactose.
The auxiliary materials comprise, by mass, 25-30 parts of inulin, 25-30 parts of fructo-oligosaccharide, 5-10 parts of sea buckthorn powder, 5-10 parts of polydextrose, 5-10 parts of lactitol, 5-10 parts of erythritol and 5-10 parts of isomerized lactose.
Bifidobacteria (bifidobacteria) are a gram-positive, immotile, rod-shaped, sometimes bifurcated, strictly anaerobic genus of bacteria found in the alimentary canal, vagina and oral cavity of humans and animals. The bifidobacterium has a plurality of important physiological functions of biological barrier, nutrition, anti-tumor, immunity enhancement, gastrointestinal tract function improvement, aging resistance and the like on human health.
Lactobacillus acidophilus can secrete antibiotic substances (acidophilic lactolin, acidophilic bacteriocin and laetocidin) to antagonize intestinal pathogenic bacteria, and has the functions of regulating intestinal flora balance, maintaining intestinal health, raising immunity, etc. In addition, lactobacillus acidophilus has extremely strong acid resistance, salt resistance and bile resistance, can grow and propagate in an acid and high-salt environment where other lactobacillus cannot grow, can utilize glucose, fructose, lactose and sucrose to perform homotypic fermentation, and besides DL-type lactic acid, fermentation metabolites also comprise bacteriocin, vitamins, small peptides and the like, can improve the utilization rate of calcium, phosphorus and iron, promote the absorption of iron and vitamin D, reduce the absorption of cholesterol, and has the effects of enhancing digestion and absorption and promoting the growth of animals.
Beneficial bacteria such as bifidobacterium, lactobacillus and the like can inhibit the growth of harmful bacteria of a human body, resist the infection of pathogenic bacteria, synthesize vitamins required by the human body, promote the absorption of the human body to mineral substances, generate organic acids such as acetic acid, propionic acid, butyric acid, lactic acid and the like to stimulate the intestinal tract to creep, promote defecation, prevent constipation, inhibit the intestinal tract putrefaction, purify the intestinal tract environment, decompose carcinogenic substances, stimulate the immune system of the human body, and have important effects in the aspects of improving the disease resistance and the like.
The lactobacillus rhamnosus is gram-positive facultative anaerobe without plasmid; lactose is not available, but monosaccharides are metabolized; it grows well under anaerobic conditions and also in the presence of CO. The lactobacillus rhamnosus is one of normal flora of human body, has high intestinal adhesion rate and strong colonization ability, and has the effects of balancing and improving gastrointestinal tract function, enhancing human body autoimmune ability, promoting the growth of bifidobacterium and lactobacillus acidophilus, preventing and helping to treat diarrhea, preventing respiratory tract infection, discharging toxin, preventing dental caries, preventing allergy, etc.
The isomerized lactose is the best sugar source for the growth of the bifidobacteria, is not decomposed in the small intestine and can be used by all the bifidobacteria when being moved into the large intestine, so that the bifidobacteria are predominantly grown, the growth of putrefactive bacteria and pathogenic bacteria is inhibited, and the isomerized lactose plays an important role in changing intestinal flora, keeping the normal function of the intestinal tract, preventing and treating diseases, resisting aging and the like; bifidobacterium in intestine is proliferated, pH is reduced, intestinal peristalsis is promoted, feces is softened, defecation amount and frequency are increased, and intestinal cancer is prevented by shortening intestinal retention time of useless substances which are easy to cause putrefying bacteria growth in intestine.
Lactobacillus paracasei LPC-37 can tolerate low pH value and survive in bile juice, can adhere to the mucosa on the inner wall of the intestinal tract, prolong the lodging time in the intestinal tract, enhance the muscle, regulate the response of the immune system, protect the human body against exogenous pathogen infection and limit the invasion of the pathogen in the intestinal tract. It can be combined with Lactobacillus acidophilus NCFM to promote gastrointestinal health, improve immunity, and prevent and resist influenza bacteria.
Example 1
The probiotic composition A comprises 5g of lactobacillus acidophilus, 6g of bifidobacterium lactis, 2g of lactobacillus rhamnosus, 2g of lactobacillus paracasei, 2g of bifidobacterium animalis, 2g of lactobacillus plantarum and 4g of lactic acid bacteria, 6g of isomerized lactose, 25g of inulin, 20g of fructo-oligosaccharide, 5g of sea buckthorn powder, 5g of erythritol, 5g of polydextrose and 5g of lactitol.
Example 2
The probiotic composition B comprises 10g of lactobacillus acidophilus, 10g of bifidobacterium lactis, 2g of lactobacillus rhamnosus, 2g of lactobacillus paracasei, 2g of bifidobacterium animalis, 2g of lactobacillus plantarum and 4g of lactic acid bacteria, 6g of isomerized lactose, 20g of inulin, 15g of fructo-oligosaccharide, 5g of sea buckthorn powder, 5g of erythritol, 5g of polydextrose and 5g of lactitol.
Example 3
The probiotic composition C comprises 7g of lactobacillus acidophilus, 8g of bifidobacterium lactis, 2g of lactobacillus rhamnosus, 2g of lactobacillus paracasei, 2g of bifidobacterium animalis, 2g of lactobacillus plantarum and 6g of lactic acid bacteria, 6g of isomerized lactose, 20g of inulin, 15g of fructo-oligosaccharide, 5g of sea buckthorn powder, 5g of erythritol, 5g of polydextrose and 5g of lactitol.
Example 4
The probiotic composition D comprises 8g of lactobacillus acidophilus, 8g of bifidobacterium lactis, 2g of lactobacillus rhamnosus, 2g of lactobacillus paracasei, 2g of bifidobacterium animalis, 2g of lactobacillus plantarum and 6g of lactic acid bacteria, 6g of isomerized lactose, 20g of inulin, 18g of fructo-oligosaccharide, 5g of sea buckthorn powder, 5g of erythritol, 5g of polydextrose and 5g of lactitol.
The following are the efficacy data of animal experiments on constipation prevention and intestinal flora improvement:
the samples prepared in the examples 1, 2, 3 and 4 are respectively used for intervening mice, the stomach filling amount is converted into 10 times of the recommended amount of the human body unit weight, after 7d and 14d of intervening, the loperamide hydrochloride is used for stomach filling to simulate functional constipation, the intestinal tract ink propulsion rate and defecation conditions of each group of mice are respectively observed, after the probiotic composition prepared in the examples 1, 2, 3 and 4 is taken, the intestinal tract propulsion rate of the mice is obviously increased, the first-grain black stool discharging time is obviously shortened, the 8h stool discharging amount is obviously increased, the water content of the feces is also increased, and the probiotic composition has the effects of preventing and relieving the constipation symptoms.
The above description is only a preferred embodiment of the present invention, and not intended to limit the scope of the present invention, and all modifications and equivalents of the present invention, which are made by the present specification and directly/indirectly applied to other related technical fields within the spirit of the present invention are included in the scope of the present invention.

Claims (10)

1. The probiotic composition is characterized by comprising 15-25 parts by mass of freeze-dried bacteria powder and 75-85 parts by mass of auxiliary materials, wherein the freeze-dried bacteria powder comprises lactobacillus acidophilus, bifidobacterium lactis, lactobacillus rhamnosus, lactobacillus paracasei, bifidobacterium animalis, lactobacillus plantarum and lactic acid bacteria, and the auxiliary materials comprise inulin, fructo-oligosaccharide, sea buckthorn powder, polydextrose, lactitol, erythritol and isomerized lactose.
2. The probiotic composition according to claim 1, wherein the freeze-dried powder comprises, by mass, 4 to 7 parts of lactobacillus acidophilus, 5 to 10 parts of bifidobacterium lactis, 2 to 4 parts of lactobacillus rhamnosus, 2 to 4 parts of lactobacillus paracasei, 2 to 4 parts of bifidobacterium animalis, 2 to 4 parts of lactobacillus plantarum and 4 to 6 parts of lactic acid bacteria.
3. The probiotic composition according to claim 1, characterized in that the lactobacillus acidophilus is lactobacillus acidophilus NCFM.
4. The probiotic composition according to claim 1, characterized in that the bifidobacterium lactis comprises bifidobacterium lactis HN-019, bifidobacterium lactis Bi-07, bifidobacterium lactis BL-04 and bifidobacterium lactis BLC 1.
5. The probiotic composition according to claim 1, characterized in that the lactobacillus rhamnosus is lactobacillus rhamnosus GG.
6. The probiotic composition according to claim 1, characterized in that the bifidobacterium animalis is bifidobacterium animalis BB-12.
7. The probiotic composition according to claim 1, characterized in that said lactobacillus paracasei is lactobacillus paracasei LPC-37.
8. The probiotic composition according to claim 1, characterized in that the bifidobacterium plantarum is bifidobacterium plantarum BG 112.
9. The probiotic composition according to claim 1, characterized in that said lactic acid bacteria are YO-MIX725 lactic acid bacteria and YO-MIX863 lactic acid bacteria.
10. The probiotic composition according to any one of claims 1 to 9, characterized in that the auxiliary materials comprise, by mass, 25 to 30 parts of the inulin, 25 to 30 parts of the fructo-oligosaccharide, 5 to 10 parts of the sea buckthorn powder, 5 to 10 parts of the polydextrose, 5 to 10 parts of the lactitol, 5 to 10 parts of the erythritol, and 5 to 10 parts of the isomerized lactose.
CN202110868732.2A 2021-07-30 2021-07-30 Probiotic compositions Pending CN113907361A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110868732.2A CN113907361A (en) 2021-07-30 2021-07-30 Probiotic compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110868732.2A CN113907361A (en) 2021-07-30 2021-07-30 Probiotic compositions

Publications (1)

Publication Number Publication Date
CN113907361A true CN113907361A (en) 2022-01-11

Family

ID=79233005

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110868732.2A Pending CN113907361A (en) 2021-07-30 2021-07-30 Probiotic compositions

Country Status (1)

Country Link
CN (1) CN113907361A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114468305A (en) * 2022-02-21 2022-05-13 江苏新申奥生物科技有限公司 Probiotic composition for relieving adverse reaction caused by excessive exercise and application thereof
CN115191609A (en) * 2022-07-13 2022-10-18 芳华国际控股(广东)有限公司 Probiotics capable of improving digestion ability

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108740251A (en) * 2018-06-15 2018-11-06 广东燕岭生命科技股份有限公司 A kind of probiotic gel candy and preparation method thereof improving constipation
CN109430666A (en) * 2018-10-15 2019-03-08 威海养经堂医药科技有限公司 A kind of Freeze-dry Powder of Probioctics solid beverage
CN109770148A (en) * 2019-03-12 2019-05-21 上海昊岳食品科技有限公司 A kind of instant type probiotics solid beverage and preparation method thereof
CN111557404A (en) * 2020-05-25 2020-08-21 上海昊岳食品科技有限公司 Digestion-aiding probiotic solid beverage and preparation method thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108740251A (en) * 2018-06-15 2018-11-06 广东燕岭生命科技股份有限公司 A kind of probiotic gel candy and preparation method thereof improving constipation
CN109430666A (en) * 2018-10-15 2019-03-08 威海养经堂医药科技有限公司 A kind of Freeze-dry Powder of Probioctics solid beverage
CN109770148A (en) * 2019-03-12 2019-05-21 上海昊岳食品科技有限公司 A kind of instant type probiotics solid beverage and preparation method thereof
CN111557404A (en) * 2020-05-25 2020-08-21 上海昊岳食品科技有限公司 Digestion-aiding probiotic solid beverage and preparation method thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114468305A (en) * 2022-02-21 2022-05-13 江苏新申奥生物科技有限公司 Probiotic composition for relieving adverse reaction caused by excessive exercise and application thereof
CN115191609A (en) * 2022-07-13 2022-10-18 芳华国际控股(广东)有限公司 Probiotics capable of improving digestion ability

Similar Documents

Publication Publication Date Title
RU2372788C2 (en) Probiotic, health- or productivity-stimulating fodder additive or portable water additive and its application
CA2787544C (en) Probiotic composition for use in the treatment of bowel inflammation
KR101255050B1 (en) Novel lactobacillus plantarum and compositions comprising the same
RU2536939C2 (en) Compositions containing probiotic and prebiotic ingredients and inorganic salts with lactoferrin
AU2010305515B8 (en) Lactobacillus plantarum strains as hypocholesterolemic agents.
US11273187B2 (en) Method and system for reducing the likelihood of developing depression in an individual
US20220193150A1 (en) Method and System for Reducing the Likelihood of Developing Depression in an Individual
EP1162987B1 (en) Pharmaceutical composition for medical and veterinary use for regenerating intestinal flora in diarrhoea or dyspeptic syndrome
CN1843385A (en) Enteral microecological formulation and its preparation process
CN113907361A (en) Probiotic compositions
WO2020098988A1 (en) Strains, composition and method of use
CN110623984A (en) Quadruple viable bacteria preparation for treating diarrhea and application thereof
JP5082048B2 (en) A novel lactic acid bacterium having immunostimulatory action and / or allergy-suppressing action and gastric juice resistance
CA2812909C (en) Compositions and methods for augmenting kidney function
JP2009084215A (en) Inflammatory bowel disease prophylactic or therapeutic agent
CN111067109A (en) Dietary fiber composition and preparation method and application thereof
O'Sullivan Genomics can advance the potential for probiotic cultures to improve liver and overall health
CN115011513A (en) Lactic acid bacteria powder for enhancing immunity, regulating intestines and stomach to control fat, losing weight and expelling toxin
US20090110663A1 (en) Method for treatment of bowel disorders
Tzortzis Development and evaluation Bimuno (R), a novel second-generation prebiotic galactooligosaccharide mixture
CN109549957A (en) The compound probiotic of energy bidirectional modulation constipation
CN108541950A (en) A kind for the treatment of and symphysis unit composition and its preparation and the application of pre- anti-caries
US11980643B2 (en) Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
CN116676230B (en) Bifidobacterium animalis capable of utilizing pullulan and application thereof
WO1999028441A1 (en) Novel bacillus subtilis with antibacterial effects

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination